You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

olaparib

Showing 1 - 25 of 230
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Breast Cancer Trial (Olaparib, 17b-estradiol)

Not yet recruiting
  • Metastatic Breast Cancer
  • (no location specified)
Jun 2, 2023

Carcinoma, Ovarian Epithelial Trial in San Fermo Della Battaglia, Padova (Olaparib, Bevacizumab)

Recruiting
  • Carcinoma, Ovarian Epithelial
  • San Fermo Della Battaglia, Como, Italy
  • +1 more
Nov 2, 2023

Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)

Not yet recruiting
  • Ovary Cancer
  • +2 more
  • Mirvetuximab Soravtansine
  • Olaparib
  • Aurora, Colorado
    University of Colorado Hospital
May 30, 2023

Gastric Cancer, GastroEsophageal Cancer Trial in Aurora, Colorado Springs, Highlands Ranch (Pembrolizumab, Olaparib,

Recruiting
  • Gastric Cancer
  • GastroEsophageal Cancer
  • Aurora, Colorado
  • +2 more
Jan 4, 2023

Pancreatic Acinar Cell Carcinoma Trial run by the National Cancer Institute (NCI) (Olaparib)

Recruiting
  • Pancreatic Acinar Cell Carcinoma
  • Olaparib
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Advanced Solid Tumor, NSCLCs Trial in Houston (Adagrasib, Olaparib)

Not yet recruiting
  • Advanced Solid Tumor
  • Non-small Cell Lung Cancers
  • Houston, Texas
    M D Anderson Cancer Center
Nov 15, 2023

Prostate Cancer Aggressiveness, Prostate Carcinoma Trial in Houston (Cabazitaxel, Carboplatin, Prednisone 5Mg)

Active, not recruiting
  • Prostate Cancer Aggressiveness
  • Prostate Carcinoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 5, 2022

Sarcoma, Sarcoma Metastatic Trial in Ann Arbor (Olaparib, Trabectedin)

Active, not recruiting
  • Sarcoma
  • Sarcoma Metastatic
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Dec 20, 2022

Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer Trial (AsiDNA, Olaparib)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • +2 more
  • (no location specified)
Jan 17, 2023

Cancer Trial in Amsterdam, Nijmegen, Rotterdam (Olaparib, Cobicistat)

Recruiting
  • Cancer
  • Amsterdam, Netherlands
  • +2 more
Oct 21, 2022

Advanced Solid Tumor, Metastatic Solid Tumor Trial (ART6043, Olaparib, Talazoparib)

Not yet recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • (no location specified)
Jun 1, 2023

Breast Cancer Trial in Los Angeles (Pembrolizumab, Olaparib)

Active, not recruiting
  • Breast Cancer
  • Los Angeles, California
    Cedars-Sinai Medical Center
Feb 1, 2023

Urothelial Carcinoma, Urothelial Cancer, Lung Tumors Trial run by the NCI (EP0057, olaparib)

Recruiting
  • Urothelial Carcinoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Metastatic Breast Cancer Trial in Taipei City, Taipei, Yuanlin (Olaparib, Chemotherapy drug)

Recruiting
  • Metastatic Breast Cancer
  • Olaparib
  • Chemotherapy drug
  • Taipei City, Please Select, Taiwan
  • +2 more
Nov 27, 2022

Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Tumors Trial run by the National Cancer Institute (NCI)

Recruiting
  • Gastroenteropancreatico Tumors
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 19, 2023

Prostate Cancer Trial in Lexington (biological, drug, radiation)

Not yet recruiting
  • Prostate Cancer
  • Pembrolizumab
  • +3 more
  • Lexington, Kentucky
    University of Kentucky
Oct 3, 2022

EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)

Recruiting
  • EGFR-Mutated Non-Small-Cell Lung Carcinoma
  • Small Cell/Neuroendocrine
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Breast Cancer Trial in Spain (Olaparib)

Terminated
  • Breast Cancer
  • Olaparib
  • Barcelona, Spain
  • +7 more
Jan 18, 2023

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a

Recruiting
  • ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
  • a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
  • Montpellier, France
  • +1 more
Nov 16, 2022

Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma Trial in Groningen (Olaparib, Lenvatinib, Sunitinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Olaparib
  • +4 more
  • Groningen, Netherlands
    University Medical Center Groningen
Jul 13, 2023

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma

Not yet recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +3 more
  • (no location specified)
Jul 28, 2023

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 12, 2023

Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8 Trial in New York

Recruiting
  • Locally Advanced Leiomyosarcoma
  • +5 more
  • Olaparib
  • +3 more
  • New York, New York
    Columbia University/Herbert Irving Cancer Center
Jan 4, 2023

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial (procedure, biological,

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +5 more
  • (no location specified)
Apr 8, 2023

Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (biological, drug, other)

Recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Durvalumab
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023